DDrare: Database of Drug Development for Rare Diseases

Progerinin (DrugBank: -)

2 diseases

ID	Disease name (Link within this page)	Number of trials
191	Werner syndrome	1
333	Hutchinson-Gilford syndrome	1

191. Werner syndrome [ 3 clinical trials, 4 drugs, (DrugBank: 3 drugs), 1 drug target gene, 5 drug target pathways]

Searched query = "Werner syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 3 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04512963 (ClinicalTrials.gov)	August 24, 2020	6/8/2020	Phase I Study of Progerinin in Healthy Volunteers	A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study Including a Food Interaction Study, Followed by a Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Profile of Progerinin in Healthy Volunteers	Hutchinson-Gilford Progeria Syndrome;Werner Syndrome	Drug: Progerinin;Drug: Placebo	PRG Science & Technology Co., Ltd.	Amarex Clinical Research	Recruiting	18 Years	45 Years	All	56	Phase 1	United States

333. Hutchinson-Gilford syndrome [ 7 clinical trials, 8 drugs, (DrugBank: 3 drugs), 4 drug target genes, 6 drug target pathways]

Searched query = "Hutchinson-Gilford syndrome", "Hutchinson-Gilford progeria syndrome", "HGPS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 7 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04512963 (ClinicalTrials.gov)	August 24, 2020	6/8/2020	Phase I Study of Progerinin in Healthy Volunteers	A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study Including a Food Interaction Study, Followed by a Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Profile of Progerinin in Healthy Volunteers	Hutchinson-Gilford Progeria Syndrome;Werner Syndrome	Drug: Progerinin;Drug: Placebo	PRG Science & Technology Co., Ltd.	Amarex Clinical Research	Recruiting	18 Years	45 Years	All	56	Phase 1	United States